CGS 13945: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6917815 |
| CHEMBL ID | 2107131 |
| SCHEMBL ID | 109520 |
| MeSH ID | M0116627 |
| Synonym |
|---|
| pentopril |
| cgs-13945 |
| D03760 |
| 82924-03-6 |
| pentopril (usan/inn) |
| (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid |
| cgs 13945 |
| pentoprilum |
| ethyl (alphar,gammar,2s)-2-carboxy-alpha,gamma-dimethyl-delta-oxo-1-indolinevalerate |
| 1-(4-(ethoxycarbonyl)-2-methylpentanoyl)-2,3-dihydroindole-2-carboxylic acid |
| pentopril [usan:inn] |
| pentoprilum [latin] |
| z99269057a , |
| unii-z99269057a |
| 1h-indole-1-pentanoic acid, 2-carboxy-2,3-dihydro-alpha,gamma-dimethyl-delta-oxo-, ethyl ester, (2s-(1(alphas*,gammas*),2r*))- |
| pentopril [mart.] |
| pentopril [who-dd] |
| 1h-indole-1-pentanoic acid, 2-carboxy-2,3-dihydro-a,g-dimethyl-d-oxo-, ethyl ester, (2s-(1(.alpha.s*,gs*),2r*))- |
| pentopril [usan] |
| pentopril [inn] |
| ethyl (.alpha.r,.gamma.r,2s)-2-carboxy-a,g-dimethyl-.delta.-oxo-1-indolinevalerate |
| CHEMBL2107131 |
| SCHEMBL109520 |
| Q27295181 |
| DTXSID601024673 |
The pharmacokinetic interaction between pentopril (250 mg) and furosemide (40 mg) was studied in 12 normal healthy volunteers after oral administration of each drug alone and in combination. There were no appreciable differences between the two groups. In the multiple-dose study of 125 mg orally q12h in six healthy subjects, the plasma concentrations for both drug and metabolite showed no appreciative accumulation of either compound.
| Excerpt | Reference | Relevance |
|---|---|---|
| " 2 There were no appreciable differences between the two groups in any of the pharmacokinetic parameters for pentopril derived from its plasma data (Cmax, tmax, AUC and t1/2)." | ( Pharmacokinetics of pentopril in the elderly. Hurley, ME; Kochak, GM; Radensky, P; Rakhit, A; Tipnis, V; Williams, R, 1987) | 0.81 |
| "The theoretical evaluation of a pharmacokinetic precursor/metabolite model was accomplished utilizing an integral approach based on clearance." | ( Determination of metabolite pharmacokinetics for orally administered prodrugs. Kochak, GM; Rakhit, A, ) | 0.13 |
| " In the multiple-dose study of 125 mg orally q12h in six healthy subjects, the plasma concentrations for both drug and metabolite showed no appreciable accumulation of either compound, which was expected from their short pharmacokinetic half-lives (pentopril, less than 1 hr; CGS 13934, approximately 2 hr)." | ( Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting-enzyme inhibitor in humans. Brunner, HR; Coleman, J; Hurley, ME; Rakhit, A; Rommel, A; Tipnis, V, 1986) | 0.72 |
| "The pharmacokinetic interaction between pentopril (250 mg) and furosemide (40 mg) was studied in 12 normal healthy volunteers after oral administration of each drug alone and in combination." | ( Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Hurley, ME; Kochak, GM; Rakhit, A; Tipnis, V, 1987) | 0.8 |
Systemic bioavailability of furosemide appears to be unchanged in the presence of pentopril (0.5 mg) The extent of apparent bioavailability was determined after oral administration ofpentopril.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Because relative bioavailability is not affected in the presence of food, such a delay may not have any therapeutic importance on chronic administration." | ( Effect of food on the bioavailability of pentopril, an angiotensin-converting-enzyme inhibitor, in healthy subjects. Coleman, J; Hurley, ME; Kochak, G; Rakhit, A; Redalieu, E; Rommel, A; Tipnis, V, 1985) | 0.54 |
| " The extent of apparent bioavailability of the active metabolite was determined after oral administration of pentopril." | ( Disposition of pentopril, a new orally active angiotensin-converting enzyme inhibitor, and its active metabolite in rats. Dotson, R; Kochak, G; Rakhit, A; Tipnis, V, 1985) | 0.83 |
| " Systemic bioavailability of furosemide appears to be unchanged in the presence of pentopril (0." | ( Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Hurley, ME; Kochak, GM; Rakhit, A; Tipnis, V, 1987) | 0.75 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because of unchanged pharmacodynamic effect, such pharmacokinetic interaction may not require any dosage adjustment for furosemide on pentopril coadministration." | ( Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Hurley, ME; Kochak, GM; Rakhit, A; Tipnis, V, 1987) | 0.73 |
| " Based on the prolonged blockade of plasma ACE activity, some correction in dose or dosing interval is anticipated in patients with moderately compromised renal function (CLCR less than 50 ml/min)." | ( Effect of renal impairment on disposition of pentopril and its active metabolite. Audet, PR; Feldman, GM; Hurley, ME; Kochak, GM; Radensky, P; Rakhit, A; Szerlip, HM, 1988) | 0.53 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 13 (72.22) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (4.76%) | 5.53% |
| Reviews | 1 (4.76%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (90.48%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||